Hochuekkito is often discussed by people searching for relief from Long COVID or ME/CFS. The interest is understandable. A laboratory study suggested that Hochuekkito influenced virus-related cellular energy changes, and a 2023 case report described recovery in a woman with post-COVID illness meeting ME/CFS criteria. The key point is simple: these signals are interesting, but they do not prove that Hochuekkito alone is an established treatment.
What Hochuekkito is
Hochuekkito is a traditional Japanese Kampo formula used in contexts such as fatigue, weakness, and difficult recovery. That background helps explain why it appears in discussions about Long COVID and ME/CFS.
This does not make it ineffective, but it does matter for interpretation. Hochuekkito is not a single modern drug with one isolated mechanism. It is a multi-ingredient traditional formula, so strong clinical claims require strong clinical evidence.
What the laboratory study found
The study indexed at PubMed as “Examination of the effect of Hochuekkito on mitochondrial function and glycolysis in influenza virus-infected cells” was not conducted in people with Long COVID or ME/CFS. It used cultured MDCK cells infected with influenza A/H1N1.
The researchers measured two markers:
- OCR: oxygen consumption rate, used here as a marker of mitochondrial respiration
- ECAR: extracellular acidification rate, used here as a marker related to glycolysis
In that model, viral infection disturbed the balance between these energy-related pathways. Cells pretreated with Hochuekkito showed a metabolic profile closer to uninfected cells.
What that means
This is a useful mechanistic finding. It suggests that Hochuekkito may influence how infected cells handle energy stress in a laboratory model.
What it does not mean
It does not show that Hochuekkito treats Long COVID in humans. It does not prove benefit in ME/CFS. It shows a biologically interesting effect in an influenza cell model, not a confirmed clinical outcome.
The 2023 case report of a 55-year-old woman
The full-text case report published in 2023, “Improvement of long COVID symptoms and ME/CFS with cognitive behavioral therapy and medication”, described a 55-year-old nurse who remained severely unwell more than six months after COVID-19 pneumonia.
Her reported problems included:
- severe fatigue
- PEM
- shortness of breath
- pain
- cognitive symptoms
- tachycardia
The report states that her condition met criteria for Long COVID and was compatible with ME/CFS.
What treatment she received
This is the central detail many summaries miss. She did not receive Hochuekkito alone. The reported care included:
- dietary advice and supplements
- management of physical, cognitive, and emotional fatigue
- very gradual activity adjustment
- amitriptyline 10 mg
- Hochuekkito 7.5 g
Her symptoms improved over several weeks, and the report describes eventual recovery and return to work.
What should be retained from this case
This case is encouraging, but it cannot prove causation.
There are four reasons:
- It is a single case.
- The intervention was multimodal, not Hochuekkito alone.
- There was no control group.
- Natural recovery may have contributed.
The careful reading is therefore not, “Hochuekkito cured Long COVID.” The careful reading is, “One patient improved after a combined treatment plan that included Hochuekkito.”
That distinction is not technical hair-splitting. It is the difference between evidence and projection.
The practical conclusion
People searching for “Hochuekkito Long COVID” or “Hochuekkito ME/CFS” are usually looking for something solid. At present, the evidence is still early.
What can be said safely:
- Hochuekkito has a traditional use context related to fatigue and weakness.
- A cell study found a potentially relevant metabolic effect in influenza-infected cells.
- A 2023 case report described recovery in one woman with post-COVID illness meeting ME/CFS criteria after a broader treatment plan that included Hochuekkito.
What cannot be said safely:
- that Hochuekkito alone has been proven to treat Long COVID
- that Hochuekkito alone has been proven to treat ME/CFS
- that a laboratory signal or one case report is enough to guide firm conclusions
The right stance is neither dismissal nor hype. It is careful interest with clear limits.
Sources
- PubMed: Examination of the effect of Hochuekkito on mitochondrial function and glycolysis in influenza virus-infected cells
- PubMed Central: Improvement of Long COVID symptoms and ME/CFS in a 55-year-old woman after combined treatment
- World Health Organization: Post COVID-19 condition (Long COVID) fact sheet
- NICE: ME/CFS guideline with post-exertional malaise definition